Cys-C
ZECEN
DR1049
| Name: | |
|---|---|
| Luminous System: | |
| Calibrator: | |
| Quality Control: | |
| Storage: | |
| Quantity: | |
SUMMARY AND EXPLANATION OF THE TEST
Cystatin C (Cys-C) detection kit (CLIA) (hereinafter referred to as the kit), is used for the in vitro quantitative determination of cystatin C (Cys-C) concentration in human serum, which is an important indicator to assess renal function in kidney transplant .
Cancer treatment can damage kidney function, and therefore Cystatin C is used as an early indicator of renal damage. It is used to adjust the dose to prevent irreversible kidney damage. Lower protein intake in cancer patients or muscle consumption can prevent increased creatinine levels of renal failure. Therefore, cystatin C assay provides important information for renal function.
Cystatin C is a kind of cysteine protease inhibitor, also known as γ--trace protein and post-γ- globulin, widely presents in nucleated cells and body fluids in various tissues. It is a kind of non-glycosylated protein of low molecular weight coded by the CST3 gene. Its molecular weight is 13.3KD, comprising 122 pcs of amino acid residues, which can be generated by all nucleated cells with a constant rate. Circulating cystatin C will be cleared by glomerular filtration, and reabsorbed by proximal tubule, but then all the reabsorbed Cys-C will be metabolic broke down, and do not return to the blood. And therefore Cys-C concentration in the blood is determined by glomerular filtration without relying on any external factors, such as gender, age, diet, It is and ideal homology marker to reflect changes in glomerular filtration rate.
PRINCIPLE OF THE TEST
Sandwich meth
Cys-C Antibody labeled by FITC and Cys-C Antibody pair labeled by AP bind with te Cys-C antigen in the sample, control or calibrator and form sandwich complex. Then add the magnetic beads binding with Anti-FITC, through the specific binding between the FITC and Anti-FITC, the complex will be bound by the magnetic beads. Then the entire complex will be captured by the external applied magnetic field and separate from the unbound substance. Afte washing, add the substrate. The substrate will be catalytically cracked under the action of the enzyme, and form an unstable intermediate in excited state. When the intermediate in excited state returns to the ground state, it will issue photons and make a light-emitting reaction. Then the CLIA analyzer will measure the luminous intensity and count the results through software by comparing the luminous intensity with the cutoff value to determine whether the corresponding antibody exists.
